Reason for request
Inclusion on the list of medicines reimbursed by National Health Insurance and approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of ADENUIRC is substantial. |
Clinical Added Value
| minor |
The Transparency Committee considers that ADENURIC provides a minor improvement in actual benefit (level IV) in the management of symptomatic chronic hyperuricaemia compared to the current therapeutic strategy based on allopurinol. |
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
GvY4xK2XTzuNLhpP
